Belantamab mafodotin - GSK
Alternative Names: anti-BCMA-ADC - GSK ; Belamaf; belantamab mafodotin-blmf; blenrep; BLENREP; GSK'916; GSK-2857916; J6M0-mcMMAFLatest Information Update: 12 Jun 2024
At a glance
- Originator GlaxoSmithKline
- Developer Amgen; Atrium Health; GSK
- Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Multiple myeloma
- Phase II Plasmablastic lymphoma
Most Recent Events
- 07 Jun 2024 Efficacy and adverse events data from a phase III DREAMM-7 trial in multiple melanoma released by GlaxoSmithKline
- 03 Jun 2024 Efficacy and adverse events data from a phase III DREAMM 8 trial in Multiple myeloma released by GSK
- 31 May 2024 Updated efficacy and adverse event data from the phase III DREAMM-7 trial in Mutiple myeloma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)